Physician profile
James N Powers
NPI 1962602516
$1,655.63
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $302 · 2021: $218 · 2022: $247.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $445.43 | 2019-2022 | |
| Gilead Sciences, INC. | $415.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $321.12 | 2019-2020 | |
| Janssen Products, LP | $168.99 | 2021-2022 | |
| Abbvie INC. | $55.83 | 2019-2022 | |
| Melinta Therapeutics, LLC | $52.85 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $36.36 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $33.00 | 2021 | |
| Allergan, INC. | $25.05 | 2019-2020 | |
| Astellas Pharma US INC | $17.47 | 2020 | |
| Vyera Pharmaceuticals, LLC | $15.90 | 2020 | |
| Janssen Biotech, INC. | $15.65 | 2020 | |
| Napo Pharmaceuticals INC | $14.53 | 2020 | |
| Dynavax Technologies Corporation | $14.24 | 2020 | |
| Nabriva Therapeutics, Plc | $12.50 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $11.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.